Centaurus Financial Inc. Sells 48 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Centaurus Financial Inc. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117 shares of the biopharmaceutical company’s stock after selling 48 shares during the period. Centaurus Financial Inc.’s holdings in Regeneron Pharmaceuticals were worth $103,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Sierra Summit Advisors LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $1,011,000. V Square Quantitative Management LLC raised its stake in Regeneron Pharmaceuticals by 68.9% in the fourth quarter. V Square Quantitative Management LLC now owns 760 shares of the biopharmaceutical company’s stock worth $668,000 after buying an additional 310 shares in the last quarter. Oracle Alpha Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $609,000. Profund Advisors LLC raised its stake in Regeneron Pharmaceuticals by 15.0% in the fourth quarter. Profund Advisors LLC now owns 11,689 shares of the biopharmaceutical company’s stock worth $10,266,000 after buying an additional 1,523 shares in the last quarter. Finally, Forefront Analytics LLC raised its stake in Regeneron Pharmaceuticals by 8.9% in the fourth quarter. Forefront Analytics LLC now owns 319 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 26 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on REGN shares. Truist Financial restated a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Royal Bank of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Monday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $998.09.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,535 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,437,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Michael S. Brown sold 1,535 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,437,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the sale, the chief executive officer now owns 466,877 shares in the company, valued at $457,179,964.71. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,215 shares of company stock worth $60,414,782. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.6 %

REGN opened at $1,039.11 on Thursday. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $1,052.34. The company has a market capitalization of $114.50 billion, a PE ratio of 30.70, a PEG ratio of 2.16 and a beta of 0.13. The firm’s 50 day simple moving average is $962.39 and its two-hundred day simple moving average is $940.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.